Pharmaceutical News

RSS

3SBio and Isotechnika enter strategic agreement for voclosporin in China

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products and Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, today announced the signing of a development and commercialization agreement for voclosporin.

24 Aug 2010

Aileron Therapeutics, Roche partner to develop, commercialise Stapled Peptide Therapeutics

Aileron Therapeutics and Roche announced today that they have entered into a collaboration to discover, develop and commercialise a new class of drugs called Stapled Peptide Therapeutics. As part of this agreement, Roche will work with Aileron to develop drug candidates against up to five undisclosed targets selected from Roche's key therapeutic areas, which include oncology, virology, inflammation, metabolism and CNS.

24 Aug 2010

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Raptor Pharmaceutical Corp.,provides updates on timelines related to its clinical programs including the pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

24 Aug 2010

Deutsches Ärzteblatt International presents new PRISCUS List

In the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2010; 107[31-32]: 543-51), Stephanie Holt, a clinical pharmacologist, and coauthors present the PRISCUS List: a list of medications that carry an increased risk of side effects when given to elderly patients.

24 Aug 2010

Department of Health to hold vaccination drive for whooping cough

With some areas of the state seeing an increase in whooping cough, known medically as pertussis, the Department of Health urges all Pennsylvanians to ensure they are protected against the vaccine-preventable disease.The department will soon hold public vaccination clinics in York and Delaware counties, where cases of pertussis have been rising.

24 Aug 2010

OSDD program aims to develop new drug for tuberculosis

An unlikely effort is underway to lift the veil of nearly-total secrecy that has surrounded the process of developing new prescription drugs for the last century, scientists said today at the 240th National Meeting of the American Chemical Society (ACS). The upheaval in traditional practice would make key data available to college students, university professors, and others in an open, collective process.

24 Aug 2010

Medivir appoints Daewoong as South Korean distributor for Xerclear

Medivir AB today announced it has appointed Daewoong Pharmaceutical Co. Ltd. as its exclusive distributor for Xerclear™ in South Korea. Under the terms of the agreement, Daewoong will be responsible for obtaining the regulatory approvals, and for marketing, sales and distribution of Medivir's cold sore product in the territory. In consideration of the rights granted to Daewoong, Medivir will receive upfront and milestone payments and royalties on sales according to a profit sharing scheme.

24 Aug 2010

Removing corticosteroid regimen after surgery results in better graft survival rates

University of Cincinnati (UC) analysis of 10 years of data from local kidney transplant patients shows that patients removed from a corticosteroid regimen shortly after surgery have better graft survival rates, better survival rates and fewer cardiovascular events than patients kept on the traditional regimen of long-term steroids.

24 Aug 2010

Baxter announces definitive agreement with Kamada for GLASSIA alpha1-proteinase inhibitor

Baxter International Inc. today announced a definitive agreement with Kamada Ltd. for exclusive commercial rights to GLASSIA™ [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid alpha1-proteinase inhibitor, in the United States, Australia, New Zealand and Canada.

From Baxter International Inc. 24 Aug 2010

AP reports on efforts to monitor authenticity of antimalarials, other drugs in Africa

The Associated Press reports on a recent effort to use text messages to track the authenticity of antimalarials in Africa, where "more than 30 percent of malaria medicines are estimated to be fake."

24 Aug 2010

Pfizer's Prevenar 13-valent pneumococcal conjugate vaccine receives WHO prequalification

The World Health Organization (WHO) has granted prequalification to Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed])for active immunization of infants and children from 6 weeks through five years of age against invasive disease, pneumonia and otitis media caused by the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) contained in the vaccine.

24 Aug 2010

Publix Super Markets to introduce flu immunization program

"Flu clinics are an extension of the services our pharmacies provide to our customers as a convenient and affordable way to receive their vaccinations," said Maria Brous, Publix director of media and community relations. "At Publix, our pharmacies are dedicated to building relationships with our customers and their families for total health and wellness all year long."

23 Aug 2010

Preclinical studies of BIND-014 to be presented at ACS National Meeting

BIND Biosciences announced today the presentation of its Medicinal Nanoengineering platform at the ACS National Meeting, including results from preclinical studies on its lead nanomedicine drug , BIND-014, scheduled to enter clinical trials later this year. BIND-014 is a targeted, polymeric nanoparticle containing the cytotoxic agent, docetaxel, which is approved in major cancer indications, including breast, prostate and lung.

23 Aug 2010

Flu vaccine to be available at local pharmacies, doctor's offices

Flu vaccine will soon be available at local pharmacies and doctor's offices, and government officials are urging everyone over 6 months of age to receive it. This year's vaccine protects against H1N1 and two other strains of seasonal flu.

23 Aug 2010

Novo Nordisk reaches exclusive agreement to market Vagifem 10 mcg

Novo Nordisk Inc. today announced that it has signed an exclusive agreement with Upsher-Smith Laboratories, Inc. to market Vagifem (estradiol vaginal tablets) 10 mcg. Under the terms of the agreement, Upsher-Smith will exclusively market Vagifem 10 mcg to physicians in the U.S. beginning August 2 through the company's existing field sales force.

23 Aug 2010

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

Alexion Pharmaceuticals, Inc. today announced that the US Food and Drug Administration (FDA) has approved Alexion's Rhode Island manufacturing facility (ARIMF) in Smithfield, Rhode Island as a second source of commercial supply for Soliris® (eculizumab).

23 Aug 2010

Getinge's vascular graft production unit receives warning letter from FDA

Getinge's production unit in Wayne, New Jersey, US, has received a warning letter from the US FDA (Food and Drug Administration). The warning letter originates from an inspection performed by the authority on the Wayne plant during the spring of 2010. The FDA's observations and remarks relate to the manufacture of vascular grafts

23 Aug 2010

Researchers find medication for diabetes, smoking cessation

The script for two research teams inducted today into the American Chemical Society (ACS) scientific "hall of fame" the ACS Heroes of Chemistry is a tale of two pills. One team invented a medication that helps people with diabetes control their blood sugar levels. The second team invented a medicine that helps people stop smoking, an addiction that experts regard as today's single greatest preventable cause of death worldwide.

23 Aug 2010

Epicept receives refusal to file letter on new drug application

EpiCept Corporation today announced that it received a refusal to file letter from the U.S. Food and Drug Administration (FDA) on the New Drug Application (NDA) for Ceplene(histamine dihydrochloride).

23 Aug 2010

New antisense drugs may help treat accidental infections: Study

New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposure-suggesting the approach holds promise for treating accidental infections in laboratory or hospital settings.

23 Aug 2010

Pharmaceutical News

3SBio and Isotechnika enter strategic agreement for voclosporin in China

Aileron Therapeutics, Roche partner to develop, commercialise Stapled Peptide Therapeutics

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Deutsches Ärzteblatt International presents new PRISCUS List

Department of Health to hold vaccination drive for whooping cough

OSDD program aims to develop new drug for tuberculosis

Medivir appoints Daewoong as South Korean distributor for Xerclear

Removing corticosteroid regimen after surgery results in better graft survival rates

Baxter announces definitive agreement with Kamada for GLASSIA alpha1-proteinase inhibitor

AP reports on efforts to monitor authenticity of antimalarials, other drugs in Africa

Pfizer's Prevenar 13-valent pneumococcal conjugate vaccine receives WHO prequalification

Publix Super Markets to introduce flu immunization program

Preclinical studies of BIND-014 to be presented at ACS National Meeting

Flu vaccine to be available at local pharmacies, doctor's offices

Novo Nordisk reaches exclusive agreement to market Vagifem 10 mcg

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

Getinge's vascular graft production unit receives warning letter from FDA

Researchers find medication for diabetes, smoking cessation

Epicept receives refusal to file letter on new drug application

New antisense drugs may help treat accidental infections: Study

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News